These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 10103212

  • 1. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
    Muñoz Bellido JL, Alonso Manzanares MA, Yagüe Guirao G, Gutiérrez Zufiaurre MN, Toldos MC, Segovia Hernández M, Garcia-Rodríguez JA.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):966-8. PubMed ID: 10103212
    [Abstract] [Full Text] [Related]

  • 2. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M, Yonezawa M, Kurose S, Futakuchi N, Matsubara N, Watanabe Y, Narita H.
    J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
    [Abstract] [Full Text] [Related]

  • 3. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.
    Muñoz-Bellido JL, Alonzo Manzanares M, Martínez Andrés JA, Guttiérrez Zufiaurre MN, Ortiz G, Segovia Hernández M, García-Rodríguez JA.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):354-6. PubMed ID: 9925531
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G, Martínez-Toldos MC, Alonso Manzanares MA, Gutiérrez Zufiaurre MN, Martínez-Andrés JA, Muñoz Bellido JL, García-Rodríguez JA, Segovia Hernández M.
    Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [Abstract] [Full Text] [Related]

  • 8. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D.
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.
    Noguchi N, Okihara T, Namiki Y, Kumaki Y, Yamanaka Y, Koyama M, Wakasugi K, Sasatsu M.
    Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M, Wang T, Onodera Y, Uchida Y, Sato K.
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [Abstract] [Full Text] [Related]

  • 14. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F.
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [Abstract] [Full Text] [Related]

  • 15. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
    Takahashi H, Kikuchi T, Shoji S, Fujimura S, Lutfor AB, Tokue Y, Nukiwa T, Watanabe A.
    J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
    [Abstract] [Full Text] [Related]

  • 16. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
    Schmitz FJ, Jones ME, Hofmann B, Hansen B, Scheuring S, Lückefahr M, Fluit A, Verhoef J, Hadding U, Heinz HP, Köhrer K.
    Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
    [Abstract] [Full Text] [Related]

  • 17. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
    Wang T, Tanaka M, Sato K.
    Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
    [Abstract] [Full Text] [Related]

  • 18. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
    Kaatz GW, Seo SM.
    Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
    [Abstract] [Full Text] [Related]

  • 19. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ, Min YH, Jo YW, Shim MJ, Choi EC.
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [Abstract] [Full Text] [Related]

  • 20. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
    Pan XS, Hamlyn PJ, Talens-Visconti R, Alovero FL, Manzo RH, Fisher LM.
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.